RT Journal Article
SR Electronic
T1 Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.03.20187526
DO 10.1101/2020.09.03.20187526
A1 Aponte Torres, Zuleika
A1 Lopez-Leon, Sandra
A1 Muthuvel, Thirumugam
A1 Manivannan, Subha
A1 Srivastava, Krutika
A1 Pavesi, Marco
YR 2020
UL http://medrxiv.org/content/early/2020/09/10/2020.09.03.20187526.abstract
AB Objective: To systematically review the safety and efficacy outcomes of using antivirals for the treatment of COVID-19. Methods: Five databases were screened from inception to 27-Aug-2020. The effects of specific drug interventions on safety and efficacy were assessed in COVID-19 patients. Risk Ratios (RRs) with corresponding 95% confidence intervals (CIs) were pooled using random-effects models. Results: A total of 10 studies were identified which fulfill the inclusion criteria. Patients taking antivirals had 26% less risk of having a severe adverse event (SAE) compared to controls (RR, 0.74, CI:0.62 to 0.89, P=0.002). Clinical improvement at day 14 was observed among the cases treated with antivirals compared to the control group (RR 1.24, CI: 1.00 to 1.53 p=0.05). Conclusion: There is evidence that Remdesivir and LPV/r reduces the hospital length of stay and that patients to which antivirals were administered had less SAE and improvement when compared to patients not prescribed with antivirals. Due to a lack of power and the quality of the studies, it was not possible to determine which antivirals have a greater risk-benefit balance, and therefore the optimal approach to antiviral treatment is still uncertain. Keywords: Antiviral agents; COVID-19; SARS-CoV-2; meta-analysis; systematic literature review.Competing Interest StatementSandra Lopez Leon works at Novartis Pharmaceuticals. The views and opinions expressed in this article do not represent any official policy or position of Novartis and its affiliated companies. Funding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval is needed, is a meta-analysisAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the supplementary document